MMG22: A Novel Bivalent Ligand for the Treatment of Neuropathic Pain
2020-10
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
MMG22: A Novel Bivalent Ligand for the Treatment of Neuropathic Pain
Authors
Published Date
2020-10
Publisher
Type
Thesis or Dissertation
Abstract
Functional interactions between the mu opioid receptor (MOR) and the metabotropic glutamate receptor 5 (mGluR5) in pain and analgesia have been well established. MMG22 is a bivalent ligand containing MOR agonist (oxymorphamine) and mGluR5 antagonist (MPEP) pharmacophores tethered by a 22-atom linker. MMG22 has been shown to produce potent analgesia in several models of chronic inflammatory and neuropathic pain. This study assessed the efficacy of systemic administration of MMG22 at reducing pain behavior in the spared nerve injury (SNI) model of neuropathic pain in mice, as well as its side effect profile and abuse potential. MMG22 reduced mechanical hyperalgesia and spontaneous ongoing pain after SNI, with greater potency early (10 days) as compared to late (30 days) after injury. Systemic administration of MMG22 did not induce place preference in naïve animals, suggesting absence of abuse liability when compared to traditional opioids. MMG22 also lacked the central locomotor, respiratory, and anxiolytic side effects of its monomeric pharmacophores. Evaluation of mRNA expression showed the transcripts for both receptors were co-localized in cells in the dorsal horn of the lumbar spinal cord and dorsal root ganglia. Teased nerve fiber recordings from the sural nerve of SNI mice show that MMG22 reduces the firing rate of C and Aδ fiber nociceptors evoked by suprathreshold stimuli. Thus, MMG22 reduces hyperalgesia after injury in the SNI model of neuropathic pain by decreasing nociceptor activity without the typical centrally mediated side effects associated with traditional opioids.
Description
University of Minnesota Ph.D. dissertation. October 2020. Major: Neuroscience. Advisor: Donald Simone. 1 computer file (PDF); vi, 180 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Speltz Paiz, Rebecca. (2020). MMG22: A Novel Bivalent Ligand for the Treatment of Neuropathic Pain. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/225877.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.